Neurocrine Biosciences Stock News

Neurocrine Biosciences (NASDAQ: NBIX ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 4 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 2 0 0 2M Ago 0 1 2 0 0 3M Ago 1 1 0 0 0 In the last 3 months, 8 analysts have offered 12-month price targets for Neurocrine Biosciences. The company has an average price target of $110.75 with a high of $154.00 and a low of $90.00. Below is a summary of how these 8 analysts rated Neurocrine Biosciences over the past … Full story available on Benzinga.com

Goldman Sachs has upgraded shares of Neurocrine Biosciences (NBIX) to buy from hold based on its solid balance sheet and catalysts coming in the next 12-18 months.

Upgrades According to 86 Research, the prior rating for NetEase Inc (NASDAQ:NTES) was changed from Hold to Buy. For the fourth quarter, NetEase had an EPS of $1.56, compared to year-ago quarter EPS o

Neurocrine exited 2021 with high single-digit qoq growth in Ingrezza prescriptions, but management is investing even more SG&A resources into recharging sales growth and momentum.

NBIX earnings call for the period ending December 31, 2021.

NBIX earnings call for the period ending December 31, 2021.

Neurocrine Biosciences Inc (NASDAQ: NBIX) reported Q4 Ingrezza sales of $301 million, +25% Y/Y, with total prescriptions up 32% Overall sales increased $312.0 million 26%, missing the consensus of

Neurocrine Biosciences Inc (NASDAQ: Full story available on Benzinga.com

Recording the biggest intraday gain since March 2021, Neurocrine Biosciences <> is trading sharply higher on above-average volume despite its lower-than-expected financials for…

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-Developed Oncology Drug Eli Lilly

Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2021 Results - Earnings Call Transcript

INGREZZA® (valbenazine) 2021 Net Product Sales of $1.1 Billion with 200,000 TRx INGREZZA® (valbenazine) 2022 Net Product Sales Guidance of $1.25 - $1.35 Billion Expanded Pipeline Expected to Deliver Multiple Registrational and Phase 2 Study Data Readouts Over the Next Two Years SAN DIEGO , Feb.

Neurocrine Biosciences Inc (NASDAQ: NBIX) reported Q4 Ingrezza sales of $301 million, +25% Y/Y, with total prescriptions up 32% Overall sales increased $312.0 million 26%, missing the consensus of $